Issued Patents All Time
Showing 25 most recent of 59 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12421252 | Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease | Jianguo CHEN, Weixing Zhang, Zhisen Zhang | 2025-09-23 |
| 12421240 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | Hongtao Xu, Zhisen Zhang, Ge Zou | 2025-09-23 |
| 12421229 | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease | Jianguo CHEN, Fabian Dey, Hongtao Xu, Weixing Zhang | 2025-09-23 |
| 12351575 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen +5 more | 2025-07-08 |
| 12252484 | Pyrazolopyridine compounds for the treatment of autoimmune disease | Fabian Dey, Taishan Hu, Haixia Liu, Hong Shen, Zhiwei Zhang | 2025-03-18 |
| 12247036 | Tricyclic compounds for the treatment of cancer | Jianguo CHEN, Lei Guo, Haixia Liu, Hong Shen, Junwei Xi +2 more | 2025-03-11 |
| 12173045 | Human alpha fetoprotein-specific t cell receptors and uses thereof | Yukai He, Esteban Celis, Yibing Peng, Lan Wang | 2024-12-24 |
| 12157746 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | Fabian Dey, Hong Shen, Hongtao Xu, Hongying Yun, Ge Zou | 2024-12-03 |
| 11952363 | Piperazine compounds for the treatment of autoimmune disease | Fabian Dey, Zongxing Qiu, Ge Zou | 2024-04-09 |
| 11873292 | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | Hong Liu, Jia-He Li, Yubo Zhou, Jiang Wang, Mingbo Su +6 more | 2024-01-16 |
| 11766412 | Methods of treating or alleviating adenylosuccinatelyase (ADSL) deficiency using spermidine or a pharmaceutically acceptable salt of spermidine | Wuguang PAN | 2023-09-26 |
| 11713327 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | Fabian Dey, Buyu Kou, Haixia Liu, Hong Shen, Xiaoqing Wang +3 more | 2023-08-01 |
| 11684593 | Applications of spermine and its derivative in preparation of antitumor drug | Wuguang PAN | 2023-06-27 |
| 11639352 | Benzothiazole compounds for the treatment of autoimmune diseases | Ge Zou, Fabian Dey | 2023-05-02 |
| 11618778 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Yihong Yao, Jiaqi Huang, Shigui ZHU, Xin Yao, Zhiyuan Li +7 more | 2023-04-04 |
| 11608369 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Yihong Yao, Jiaqi Huang, Shigui ZHU, Xin Yao, Zhiyuan Li +7 more | 2023-03-21 |
| 11548884 | Cyclic amidine compounds for the treatment of autoimmune disease | Zongxing Qiu, Hong Shen, Fabian Dey, Ge Zou, Hongtao Xu | 2023-01-10 |
| 11517541 | Applications of spermidine and its derivatives | Wuguang PAN | 2022-12-06 |
| 11504375 | ErbB/BTK inhibitors | Zhengtao LI, Hao ZOU, Changmao Shen, Rumin WANG, Wengeng LIU +4 more | 2022-11-22 |
| 11472858 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Yihong Yao, Jiaqi Huang, Shigui ZHU, Xin Yao, Zhiyuan Li +7 more | 2022-10-18 |
| 11400185 | Biocompatible smart biomaterials with tunable shape changing and enhanced cytocompatibility properties | Shida Miao, Nathan J. Castro, Lijie Zhang | 2022-08-02 |
| 11261222 | Transdermal peptide with nuclear localization ability and use thereof | Shuyu Zhang, Jianping Cao, Daojiang Yu | 2022-03-01 |
| 11213614 | Vascularized biphasic tissue constructs | Lijie Zhang, Haitao Cui | 2022-01-04 |
| 11066457 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Yihong Yao, Jiaqi Huang, Shigui ZHU, Xin Yao, Zhiyuan Li +7 more | 2021-07-20 |
| 11046671 | Dihydropyrimidinyl benzazepine carboxamide compounds | Fabian Dey, Lisha Wang, Hongying Yun, Weixing Zhang, Zhiwei Zhang | 2021-06-29 |